Detalhe da pesquisa
1.
Degree of MDM2 Amplification Affects Clinical Outcomes in Dedifferentiated Liposarcoma.
Oncologist
; 24(7): 989-996, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31019022
2.
miR-133a function in the pathogenesis of dedifferentiated liposarcoma.
Cancer Cell Int
; 18: 89, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29983640
3.
Liposarcoma: molecular targets and therapeutic implications.
Cell Mol Life Sci
; 73(19): 3711-8, 2016 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27173057
4.
The hepatocyte growth factor receptor as a potential therapeutic target for dedifferentiated liposarcoma.
Lab Invest
; 95(8): 951-61, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-26006023
5.
Correction: SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma.
Clin Cancer Res
; 28(2): 431, 2022 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35045964
6.
SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma.
Clin Cancer Res
; 22(5): 1150-60, 2016 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26475335
7.
HDAC8, A Potential Therapeutic Target for the Treatment of Malignant Peripheral Nerve Sheath Tumors (MPNST).
PLoS One
; 10(7): e0133302, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26200462